535 related articles for article (PubMed ID: 30176945)
1. Liver cancer cell lines distinctly mimic the metabolic gene expression pattern of the corresponding human tumours.
Nwosu ZC; Battello N; Rothley M; Piorońska W; Sitek B; Ebert MP; Hofmann U; Sleeman J; Wölfl S; Meyer C; Megger DA; Dooley S
J Exp Clin Cancer Res; 2018 Sep; 37(1):211. PubMed ID: 30176945
[TBL] [Abstract][Full Text] [Related]
2. Gene Network Analysis of Glucose Linked Signaling Pathways and Their Role in Human Hepatocellular Carcinoma Cell Growth and Survival in HuH7 and HepG2 Cell Lines.
Berger E; Vega N; Weiss-Gayet M; Géloën A
Biomed Res Int; 2015; 2015():821761. PubMed ID: 26380295
[TBL] [Abstract][Full Text] [Related]
3. TPX2 silencing exerts anti‑tumor effects on hepatocellular carcinoma by regulating the PI3K/AKT signaling pathway.
Huang DH; Jian J; Li S; Zhang Y; Liu LZ
Int J Mol Med; 2019 Dec; 44(6):2113-2122. PubMed ID: 31638175
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatics identification of crucial genes and pathways associated with hepatocellular carcinoma.
Gao X; Wang X; Zhang S
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30341252
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-15a-5p suppresses cancer proliferation and division in human hepatocellular carcinoma by targeting BDNF.
Long J; Jiang C; Liu B; Fang S; Kuang M
Tumour Biol; 2016 May; 37(5):5821-8. PubMed ID: 26581909
[TBL] [Abstract][Full Text] [Related]
6. Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis.
Ding Z; Ericksen RE; Escande-Beillard N; Lee QY; Loh A; Denil S; Steckel M; Haegebarth A; Wai Ho TS; Chow P; Toh HC; Reversade B; Gruenewald S; Han W
J Hepatol; 2020 Apr; 72(4):725-735. PubMed ID: 31726117
[TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNA NEAT1 promotes hepatocellular carcinoma cell proliferation through the regulation of miR-129-5p-VCP-IκB.
Fang L; Sun J; Pan Z; Song Y; Zhong L; Zhang Y; Liu Y; Zheng X; Huang P
Am J Physiol Gastrointest Liver Physiol; 2017 Aug; 313(2):G150-G156. PubMed ID: 28526689
[TBL] [Abstract][Full Text] [Related]
8. BCL2L10 inhibits growth and metastasis of hepatocellular carcinoma both in vitro and in vivo.
Bai Y; Wang J; Han J; Xie XL; Ji CG; Yin J; Chen L; Wang CK; Jiang XY; Qi W; Jiang HQ
Mol Carcinog; 2017 Mar; 56(3):1137-1149. PubMed ID: 27770580
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.
Buurman R; Gürlevik E; Schäffer V; Eilers M; Sandbothe M; Kreipe H; Wilkens L; Schlegelberger B; Kühnel F; Skawran B
Gastroenterology; 2012 Sep; 143(3):811-820.e15. PubMed ID: 22641068
[TBL] [Abstract][Full Text] [Related]
10. Upregulated TRIO expression correlates with a malignant phenotype in human hepatocellular carcinoma.
Wang B; Fang J; Qu L; Cao Z; Zhou J; Deng B
Tumour Biol; 2015 Sep; 36(9):6901-8. PubMed ID: 25851347
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of Rab5a promotes hepatocellular carcinoma cell proliferation and invasion via FAK signaling pathway.
Geng D; Zhao W; Feng Y; Liu J
Tumour Biol; 2016 Mar; 37(3):3341-7. PubMed ID: 26443539
[TBL] [Abstract][Full Text] [Related]
12. Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype.
Frau M; Ladu S; Calvisi DF; Simile MM; Bonelli P; Daino L; Tomasi ML; Seddaiu MA; Feo F; Pascale RM
J Hepatol; 2011 Jul; 55(1):111-9. PubMed ID: 21419759
[TBL] [Abstract][Full Text] [Related]
13. Identification of hepatocellular carcinoma-associated hub genes and pathways by integrated microarray analysis.
Liu F; Li H; Chang H; Wang J; Lu J
Tumori; 2015; 101(2):206-14. PubMed ID: 25768320
[TBL] [Abstract][Full Text] [Related]
14. Significant Down-Regulation of Urea Cycle Generates Clinically Relevant Proteomic Signature in Hepatocellular Carcinoma Patients with Macrovascular Invasion.
Cao Y; Ding W; Zhang J; Gao Q; Yang H; Cao W; Wang Z; Fang L; Du R
J Proteome Res; 2019 May; 18(5):2032-2044. PubMed ID: 30901224
[TBL] [Abstract][Full Text] [Related]
15. Severe metabolic alterations in liver cancer lead to ERK pathway activation and drug resistance.
Nwosu ZC; Piorońska W; Battello N; Zimmer AD; Dewidar B; Han M; Pereira S; Blagojevic B; Castven D; Charlestin V; Holenya P; Lochead J; De La Torre C; Gretz N; Sajjakulnukit P; Zhang L; Ward MH; Marquardt JU; di Magliano MP; Lyssiotis CA; Sleeman J; Wölfl S; Ebert MP; Meyer C; Hofmann U; Dooley S
EBioMedicine; 2020 Apr; 54():102699. PubMed ID: 32330875
[TBL] [Abstract][Full Text] [Related]
16. Fascin-1 expression correlates with repression of E-cadherin expression in hepatocellular carcinoma cells and augments their invasiveness in combination with matrix metalloproteinases.
Hayashi Y; Osanai M; Lee GH
Cancer Sci; 2011 Jun; 102(6):1228-35. PubMed ID: 21323792
[TBL] [Abstract][Full Text] [Related]
17. Bioinformatics Analysis Identifies Protein Tyrosine Kinase 7 (PTK7) as a Potential Prognostic and Therapeutic Biomarker in Stages I to IV Hepatocellular Carcinoma.
Zou RC; Liang Y; Li LL; Tang JZ; Yang YP; Geng YC; He J; Luo LY; Li WX; Sun ZW; Yuan HL
Med Sci Monit; 2019 Nov; 25():8618-8627. PubMed ID: 31730575
[TBL] [Abstract][Full Text] [Related]
18. Wnt status-dependent oncogenic role of BCL9 and BCL9L in hepatocellular carcinoma.
Huge N; Sandbothe M; Schröder AK; Stalke A; Eilers M; Schäffer V; Schlegelberger B; Illig T; Vajen B; Skawran B
Hepatol Int; 2020 May; 14(3):373-384. PubMed ID: 31440992
[TBL] [Abstract][Full Text] [Related]
19. Treatment with MAPKAP2 (MK2) inhibitor and DNA methylation inhibitor, 5-aza dC, synergistically triggers apoptosis in hepatocellular carcinoma (HCC) via tristetraprolin (TTP).
Tran DDH; Koch A; Allister A; Saran S; Ewald F; Koch M; Nashan B; Tamura T
Cell Signal; 2016 Dec; 28(12):1872-1880. PubMed ID: 27619201
[TBL] [Abstract][Full Text] [Related]
20. Telmisartan inhibits hepatocellular carcinoma cell proliferation in vitro by inducing cell cycle arrest.
Oura K; Tadokoro T; Fujihara S; Morishita A; Chiyo T; Samukawa E; Yamana Y; Fujita K; Sakamoto T; Nomura T; Yoneyama H; Kobara H; Mori H; Iwama H; Okano K; Suzuki Y; Masaki T
Oncol Rep; 2017 Nov; 38(5):2825-2835. PubMed ID: 29048654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
